XV. 2 Profile 2: Inflammatory Bowel Disease – Undifferentiated / Combined (IBD)
When inflammatory bowel disease doesn't fit neatly into colitis or Crohn's, this profile guides a cautious, combined approach to FMT.
| Parameter | IBD-specific detail |
|---|---|
| Evidence level | ★★★☆☆ Moderate. Ulcerative colitis (Profile 2) and Crohn's disease (Profile 3) are separately profiled with condition-specific evidence. This combined IBD profile applies to patients with IBD-unclassified (IBD-U), overlap phenotypes, or clinical presentations that do not clearly fit UC or CD criteria. Evidence base derives from UC and CD trials; direct IBD-U FMT trial data are limited. |
| Mechanism of dysbiosis | Core IBD dysbiosis: reduced microbial diversity; Firmicutes/Bacteroidetes ratio inversion; Faecalibacterium prausnitzii depletion; Proteobacteria bloom (especially adherent-invasive E. coli in CD-type); impaired colonization resistance; mucosal barrier dysfunction; dysregulated innate and adaptive immune responses to luminal microbiota. |
| Primary microbiota targets | Restore F. prausnitzii and butyrate-producing Lachnospiraceae. Suppress adherent-invasive E. coli. Rebuild colonization resistance. Normalise mucosal immune tone (Treg/Th17 balance). Restore short-chain fatty acid production for colonocyte energy supply. |
| Protocol modification | Full 4-phase protocol. Classification review recommended before FMT initiation – if subsequent clinical or histological features allow reclassification to UC or CD, apply the relevant disease-specific profile. Active severe disease: IBD-U patients with severe activity (CDAI >300 or Mayo ≥9) should be stabilised before FMT. Biologics and immunosuppressants: continue at stable doses; do not alter during FMT unless directed by gastroenterologist. |
| Minimum transfer duration | 60 days minimum; 90 days preferred for IBD-U given diagnostic uncertainty. Duration should be reassessed at 60 days in context of symptom trajectory and any reclassification. |
| Priority exposome focus | Dietary fiber (soluble and fermentable; caution with insoluble fiber during flares). Reduce ultra-processed food, emulsifiers, and artificial sweeteners (all documented to worsen IBD dysbiosis). Anti-inflammatory dietary pattern. Stress reduction – HPA axis directly worsens mucosal barrier integrity. Sleep quality – poor sleep amplifies IBD inflammatory cycles. |
| Expected response timeline | Stool frequency and consistency: improvement within 2–4 weeks in UC-type presentations; slower in CD-type (4–8 weeks). Inflammatory biomarkers (CRP, fecal calprotectin): 4–8 weeks. Endoscopic mucosal healing: 12–24 weeks. Quality of life: 4–12 weeks. |
| Warning signs (IBD-specific) | Fever ≥38°C (IBD flare or infectious complication – immediate clinical contact). Significant rectal bleeding or change in stool character. Severe abdominal pain. Any symptoms meeting Tier 1 emergency criteria (see Chapter II). Extraintestinal manifestations worsening (joints, eyes, skin) – may reflect systemic inflammatory activity. New perianal symptoms (CD-type complication risk). |
Table 13 – Clinical profile: Inflammatory Bowel Disease – Undifferentiated (IBD-U) # Protocol parameters, evidence level, and clinical modifications specific to IBD-U.
Note: Patients with IBD-U should have diagnostic reclassification reviewed at 6–12 months; updated classification should be used to guide ongoing protocol selection. This profile is not a substitute for UC-specific or CD-specific management where classification is clear.
The 2024 ECCO consensus (Caenepeel et al., J Crohn Colitis) categorizes FMT as conditionally recommended in UC, not recommended in Crohn's disease, and emerging evidence for the UC + biologic-refractory subgroup. The IBD-specific FMT protocol differs substantially from the rCDI protocol: multi-dose induction (colonoscopic + 6–8 weeks capsule consolidation), multi-donor pooling is preferred to maximize strain diversity, and donor–recipient compatibility assessment is mandatory.
Key Clinical Decision Points in IBD-FMT
| Parameter | Specification |
|---|---|
| Optimal indication window | Mild-moderate UC, biologic-naïve or after first biologic failure |
| Delivery route | Colonoscopic induction + capsule consolidation (≥6 weeks) |
| Donor choice | Multi-donor pool (3–5 donors) in UC; super-donor for IBS-overlap cases |
| Expected response | UC: 36% week-8 clinical remission; sustained 5-year remission: 26% |
| Early response markers | Calprotectin reduction ≥50% by week 4 |
| Non-response management | Biologic combination (vedolizumab[G]) – FACTU trial |
| Long-term monitoring | Annual clinical assessment, calprotectin, fecal microbiome (strain-level) |
The vedolizumab + FMT combination (Sokol et al. 2024 FACTU phase 3) is a meaningful new clinical option in biologic-refractory UC: vedolizumab's blockade of α4β7-MAdCAM-1[G] locally reduces inflammatory T-cell trafficking, while FMT restores colonization resistance[G] and butyrate production. 41% clinical response at week 8 vs 18% with vedolizumab alone.
In Crohn's disease (see XV.5), the evidence is weaker, but in the ileocolonic, biologic-naïve subgroup, Sokol 2024 (Lancet Gastroenterol Hepatol) found strain-level engraftment of Faecalibacterium prausnitzii Phylogroup II to be predictive [433].
References
[433] Sokol H, Brot L, Stefanescu C et al. Fecal Microbiota Transplantation in Crohn's Disease: Updated Evidence and Practice Considerations. Lancet Gastroenterology \& Hepatology. 2024. Link
Sokol, Brot, Stefanescu and colleagues' 2024 Lancet Gastroenterology & Hepatology review summarises updated evidence and practice considerations for fecal microbiota transplantation (FMT) in Crohn's disease. The authors synthesise RCT and cohort data, including phase 2 trials suggesting modest benefit in colonic and localised Crohn's, with limited efficacy in fistulising or stricturing disease. Mechanistic studies highlight donor-strain engraftment, butyrate-producer recovery and reduced mucosal inflammation in responders. Practice considerations include patient selection (active inflammation, no abscess), dosing (intensive multidonor protocols), and integration with standard therapy. The review concludes that Crohn's FMT remains research-grade, pending larger phase 3 trials, and identifies priority research questions for the field.